IVA
Price
$4.01Alerts
Change
+$0.06 (+1.52%)
Updated
Nov 11 closing price
Capitalization
897.69M
12 days until earnings call
Intraday BUY SELL Signals
MGTX
Price
$9.68Alerts
Change
+$0.06 (+0.62%)
Updated
Nov 11 closing price
Capitalization
864.39M
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IVA vs MGTX

IVA vs MGTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IVA vs. MGTX commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IVA is a Buy and MGTX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IVA with price predictions
Nov 10, 2026

IVA in upward trend: 10-day moving average crossed above 50-day moving average on November 05, 2026

The 10-day moving average for IVA crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on IVA as a result. In 72 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

The Moving Average Convergence Divergence (MACD) for IVA just turned positive on October 20, 2026. Looking at past instances where IVA's MACD turned positive, the stock continued to rise in 30 of 38 cases over the following month. The odds of a continued upward trend are 79%.

IVA moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +3.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVA advanced for three days, in 175 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

IVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for IVA moved out of overbought territory on November 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 18 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 53 cases where IVA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for IVA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. IVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.215) is normal, around the industry mean (3.498). P/E Ratio (-7.170) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (136.986) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for MGTX with price predictions
Nov 10, 2026

MGTX sees its Stochastic Oscillator ascends from oversold territory

On November 09, 2026, the Stochastic Oscillator for MGTX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 67 instances where the indicator left the oversold zone. In 61 of the 67 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MGTX's RSI Oscillator exited the oversold zone, 22 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on MGTX as a result. In 79 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for MGTX just turned positive on October 21, 2026. Looking at past instances where MGTX's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.

Following a +6.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGTX advanced for three days, in 213 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

MGTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for MGTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. MGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.010) is normal, around the industry mean (3.498). P/E Ratio (10.112) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.715) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
IVA vs MGTX: Fundamental Ratings
IVA
MGTX
OUTLOOK RATING
1..100
2813
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
83
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10016
PRICE GROWTH RATING
1..100
5762
P/E GROWTH RATING
1..100
2878
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MGTX's Valuation (83) in the Biotechnology industry is in the same range as IVA (99) in the null industry. This means that MGTX’s stock grew similarly to IVA’s over the last 12 months.

MGTX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IVA (100) in the null industry. This means that MGTX’s stock grew similarly to IVA’s over the last 12 months.

MGTX's SMR Rating (16) in the Biotechnology industry is significantly better than the same rating for IVA (100) in the null industry. This means that MGTX’s stock grew significantly faster than IVA’s over the last 12 months.

IVA's Price Growth Rating (57) in the null industry is in the same range as MGTX (62) in the Biotechnology industry. This means that IVA’s stock grew similarly to MGTX’s over the last 12 months.

IVA's P/E Growth Rating (28) in the null industry is somewhat better than the same rating for MGTX (78) in the Biotechnology industry. This means that IVA’s stock grew somewhat faster than MGTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IVAMGTX
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 7 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
81%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (IVA: $3.95 vs. MGTX: $9.62)
Brand notoriety: IVA and MGTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IVA: 71% vs. MGTX: 84%
Market capitalization -- IVA: $897.69M vs. MGTX: $864.39M
IVA [@Biotechnology] is valued at $897.69M. MGTX’s [@Biotechnology] market capitalization is $864.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IVA’s FA Score shows that 1 FA rating(s) are green while MGTX’s FA Score has 1 green FA rating(s).

  • IVA’s FA Score: 1 green, 4 red.
  • MGTX’s FA Score: 1 green, 4 red.
According to our system of comparison, both IVA and MGTX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IVA’s TA Score shows that 6 TA indicator(s) are bullish while MGTX’s TA Score has 6 bullish TA indicator(s).

  • IVA’s TA Score: 6 bullish, 4 bearish.
  • MGTX’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, MGTX is a better buy in the short-term than IVA.

Price Growth

IVA (@Biotechnology) experienced а -1.99% price change this week, while MGTX (@Biotechnology) price change was +1.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

IVA is expected to report earnings on Nov 23, 2026.

MGTX is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

IVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IVA has been loosely correlated with SLDB. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if IVA jumps, then SLDB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IVA
1D Price
Change %
IVA100%
+2.86%
SLDB - IVA
40%
Loosely correlated
+2.14%
MGTX - IVA
38%
Loosely correlated
+1.37%
IMNM - IVA
37%
Loosely correlated
-3.67%
CELC - IVA
37%
Loosely correlated
-4.72%
TVGN - IVA
37%
Loosely correlated
-2.05%
More

MGTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MGTX has been loosely correlated with EDIT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if MGTX jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MGTX
1D Price
Change %
MGTX100%
+1.37%
EDIT - MGTX
58%
Loosely correlated
-8.91%
SANA - MGTX
55%
Loosely correlated
-1.42%
KURA - MGTX
53%
Loosely correlated
N/A
VYGR - MGTX
51%
Loosely correlated
-8.29%
TSHA - MGTX
51%
Loosely correlated
-2.17%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HYNE18.820.58
+3.18%
Hoyne Bancorp Inc.
DHT20.810.25
+1.22%
DHT Holdings
L110.930.99
+0.90%
Loews Corp
LEGH29.74-0.65
-2.14%
Legacy Housing Corp
ELOG0.59-0.03
-4.77%
Eastern International Ltd